CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


conventional oxygenWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug1028 HFNO Wiki 1.00
drug2883 mechanical ventilation Wiki 1.00
drug492 CPAP Wiki 1.00
drug751 Dexamethasone injection Wiki 0.71
drug2950 placebo Wiki 0.27

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 pneumonia_COVIDICUS

The main manifestation of COVID-19 is acute hypoxemic respiratory failure (AHRF). In patients with AHRF, the need for invasive mechanical ventilation is associated with high mortality. Two hypotheses will be tested in this study. The first hypothesis is the benefit of corticosteroid therapy on severe COVID-19 infection admitted in ICU in terms of survival. The second hypothesis is that, in the subset of patients free of mechanical ventilation at admission, either Continuous Positive Airway Pressure (CPAP) or High-Flow Nasal Oxygen (HFNO) allows to reduce intubation rate safely during COVID-19 related acute hypoxemic respiratory failure.

NCT04344730 Acute Hypoxemic Respiratory Failure COVID-19 Drug: Dexamethasone injection Drug: placebo Procedure: conventional oxygen Procedure: CPAP Procedure: HFNO Procedure: mechanical ventilation
MeSH:Pneumonia Respiratory Insufficiency
HPO:Pneumonia

Primary Outcomes

Description: The time-to-death from all causes within the first 60 days after randomization.

Measure: The time-to-death from all causes

Time: day-60

Description: the time to need for mechanical ventilation (MV), as defined by any of the 3 criteria for intubation within the first 28 days after randomization.

Measure: The time to need for mechanical ventilation (MV)

Time: day-28.

Secondary Outcomes

Description: The cycle threshold for SARS-CoV-2 PCR at baseline, day 7 and day 10 in samples of the same origin (preferably subglottic i.e. bronchoalveolar lavage or tracheal aspiration, otherwise nasopharyngeal swab)

Measure: The viral load in the respiratory tract

Time: day-10

Description: Proportion of patients with at least one episode of any healthcare-associated infection between randomization and D28

Measure: Number of patient with at least one episode of healthcare-associated infections

Time: day-28

Description: To compare the exposition to mechanical ventilation

Measure: Number of days alive without mechanical ventilation

Time: day-28

Description: Changes in SOFA (Sepsis-related Organ Failure Assessment) score. (min = 0 for normal status max = 24 for worse status)

Measure: Measure of SOFA score

Time: day-28

Description: to compare the exposition to renal replacement therapy

Measure: Number of days alive without renal replacement therapy

Time: day-28

Description: To compare the lengths of ICU

Measure: Lengths of ICU-stay

Time: day-60

Description: To compare the lengths of hospital-stay

Measure: Lengths of hospital-stay

Time: day-60

Description: Proportion of patients with severe hypoxemia, which is defined as an oxygen saturation of less than 80% during the same interval during the interval between induction and 2 minutes after tracheal intubation

Measure: Number of patients with severe hypoxemia,

Time: day 60

Description: Proportion of patients with cardiac arrest within 1 hour after intubation

Measure: Number of patients with cardiac arrest within 1 hour after intubation

Time: day 60


Related HPO nodes (Using clinical trials)